These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 16625144)

  • 61. [Post transfusionnal iron overload].
    Rose C
    Rev Prat; 2006 Dec; 56(19):2141-5. PubMed ID: 17416052
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Iron chelation therapy in the management of transfusion-related cardiac iron overload.
    Fernandes JL
    Transfusion; 2012 Oct; 52(10):2256-68. PubMed ID: 22404719
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Deferasirox therapy in children with Fanconi aplastic anemia.
    Tunç B; Tavil B; Karakurt N; Yarali N; Azik FM; Kara A; Culha V; Ozkasap S
    J Pediatr Hematol Oncol; 2012 May; 34(4):247-51. PubMed ID: 22510772
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Safety and efficacy of 4 years of deferasirox treatment for sickle cell disease patients.
    Vlachaki E; Mainou M; Bekiari E; Vetsiou E; Tsapas A
    Hemoglobin; 2013; 37(1):94-100. PubMed ID: 23215738
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Pharmacokinetics, metabolism, and disposition of deferasirox in beta-thalassemic patients with transfusion-dependent iron overload who are at pharmacokinetic steady state.
    Waldmeier F; Bruin GJ; Glaenzel U; Hazell K; Sechaud R; Warrington S; Porter JB
    Drug Metab Dispos; 2010 May; 38(5):808-16. PubMed ID: 20097723
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Deferasirox for the treatment of iron overload in non-transfusion-dependent thalassemia.
    Taher AT; Temraz S; Cappellini MD
    Expert Rev Hematol; 2013 Oct; 6(5):495-509. PubMed ID: 24083402
    [TBL] [Abstract][Full Text] [Related]  

  • 67. A phase 1/2, dose-escalation trial of deferasirox for the treatment of iron overload in HFE-related hereditary hemochromatosis.
    Phatak P; Brissot P; Wurster M; Adams PC; Bonkovsky HL; Gross J; Malfertheiner P; McLaren GD; Niederau C; Piperno A; Powell LW; Russo MW; Stoelzel U; Stremmel W; Griffel L; Lynch N; Zhang Y; Pietrangelo A
    Hepatology; 2010 Nov; 52(5):1671-779. PubMed ID: 20814896
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study.
    Taher AT; Porter J; Viprakasit V; Kattamis A; Chuncharunee S; Sutcharitchan P; Siritanaratkul N; Galanello R; Karakas Z; Lawniczek T; Ros J; Zhang Y; Habr D; Cappellini MD
    Blood; 2012 Aug; 120(5):970-7. PubMed ID: 22589472
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Deferasirox: an update.
    Porter JB
    Hemoglobin; 2009; 33 Suppl 1():S70-5. PubMed ID: 20001635
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Deferasirox: An effective once-daily orally active iron chelator.
    Porter JB
    Drugs Today (Barc); 2006 Oct; 42(10):623-37. PubMed ID: 17136223
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Novel treatment options for transfusional iron overload in patients with myelodysplastic syndromes.
    Goldberg SL
    Leuk Res; 2007 Dec; 31 Suppl 3():S16-22. PubMed ID: 18037414
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Iron-chelating therapy with the new oral agent ICL670 (Exjade).
    Cappellini MD
    Best Pract Res Clin Haematol; 2005 Jun; 18(2):289-98. PubMed ID: 15737891
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Efficacy of Deferasirox for the treatment of iron overload in Chinese thalassaemia major patients: results from a prospective, open-label, multicentre clinical trial.
    Lai YR; Liu RR; Li CF; Huang SL; Li Q; Habr D; Martin N; Shen ZX
    Transfus Med; 2013 Dec; 23(6):389-96. PubMed ID: 24147622
    [TBL] [Abstract][Full Text] [Related]  

  • 74. In brief: Jadenu--a new formulation of deferasirox for iron overload.
    Med Lett Drugs Ther; 2016 Apr; 58(1493):e56. PubMed ID: 27101213
    [No Abstract]   [Full Text] [Related]  

  • 75. Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study.
    Gattermann N; Finelli C; Porta MD; Fenaux P; Ganser A; Guerci-Bresler A; Schmid M; Taylor K; Vassilieff D; Habr D; Domokos G; Roubert B; Rose C;
    Leuk Res; 2010 Sep; 34(9):1143-50. PubMed ID: 20451251
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Chelation efficacy and erythroid response during deferasirox treatment in patients with myeloproliferative neoplasms in fibrotic phase.
    Latagliata R; Montagna C; Porrini R; Di Veroli A; Leonetti SC; Niscola P; Ciccone F; Spadea A; Breccia M; Maurillo L; Rago A; Spirito F; Cedrone M; De Muro M; Montanaro M; Andriani A; Bagnato A; Montefusco E; Alimena G
    Eur J Haematol; 2016 Jun; 96(6):643-9. PubMed ID: 26277477
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The administration of deferasirox in an iron-overloaded dialysis patient.
    Tsai CW; Yang FJ; Huang CC; Kuo CC; Chen YM
    Hemodial Int; 2013 Jan; 17(1):131-3. PubMed ID: 22549006
    [No Abstract]   [Full Text] [Related]  

  • 78. Deferasirox induces regression of iron overload in patients with myelodysplastic syndromes.
    Wimazal F; Nösslinger T; Baumgartner C; Sperr WR; Pfeilstöcker M; Valent P
    Eur J Clin Invest; 2009 May; 39(5):406-11. PubMed ID: 19320908
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Ability of deferasirox to bind iron during measurement of iron.
    Lebitasy M; Ampe E; Hecq JD; Karmani L; Nick H; Galanti L
    Clin Chem Lab Med; 2010 Mar; 48(3):427-9. PubMed ID: 20170398
    [No Abstract]   [Full Text] [Related]  

  • 80. Acute interstitial nephritis due to deferasirox: a case report.
    Brosnahan G; Gokden N; Swaminathan S
    Nephrol Dial Transplant; 2008 Oct; 23(10):3356-8. PubMed ID: 18653899
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.